<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03011060</url>
  </required_header>
  <id_info>
    <org_study_id>JLUDBSCRH 001</org_study_id>
    <nct_id>NCT03011060</nct_id>
  </id_info>
  <brief_title>Sequential Neo-adjuvant Chemotherapy Followed by Capecitabine Vs. Conventional Adjuvant Chemotherapy in Breast Cancer</brief_title>
  <acronym>NACVCAC</acronym>
  <official_title>A Prospective Randomized Controlled Trail to Evaluate Efficacy and Safety of Sequential Neo-adjuvant Chemotherapy Plus Surgery Followed by Capecitabine Versus Conventional Postoperative Adjuvant Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>First Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>First Hospital of China Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital of Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qingdao University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baotou Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>First Hospital of Jilin University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates whether sequential neo-adjuvant chemotherapy plus surgery followed by
      Capecitabine could achieve additional benefits over traditional postoperative chemotherapy.
      In the study group, patients that do not achieve pathological complete response(pCR) will
      receive sequential neo-adjuvant chemotherapy followed by Capecitabine. In the control group,
      patients will be treated with postoperative adjuvant chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Neo-adjuvant chemotherapy(NAC) is a standard treatment for locally advanced breast
      cancer(LABC). By down-staging LABC, NAC is able to make inoperable cases operable as well as
      to make breast conserving surgery an option again for some patients.Neo-adjuvant chemotherapy
      is more and more widely used in operable breast cancer since it provides critical information
      on chemotherapy response. However, only 15% to 20% of the patients can benefit from
      Neo-adjuvant chemotherapy and achieve pCR. Although we obtained the information chemotherapy
      response for the rest of the patients who received Neo-adjuvant chemotherapy, there are still
      controversies on how the information will be used for further treatment. Therefore, it is a
      problem that needs resolving how these patients can benefit from the information Neo-adjuvant
      chemotherapy provides and whether Neo-adjuvant chemotherapy can replace conventional adjuvant
      chemotherapy at all. Our study aims to make Neo-adjuvant chemotherapy benefit more patients.

      Registered patients in stage Ⅰ- Ⅲ A breast cancer is randomly split into two groups(study
      group and control group).In the study group, patients achieving pCR will be followed up for 5
      years while patients that do not achieve pCR after neo-adjuvant chemotherapy will be treated
      with Capecitabine for 8 cycles after surgery. On the other hand, patients in the control
      group will accept surgeries and conventional adjuvant chemotherapies. Follow-up study will
      last 5 years. DFS and OS will be compared between the two groups.

      This study provides an important basis and methods for the further treatment of patients
      after neo-adjuvant chemotherapy. It discusses whether neo-adjuvant chemotherapy could replace
      conventional adjuvant chemotherapy and become a new standard for breast cancer treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">February 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival(DFS)</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival(OS)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">1588</enrollment>
  <condition>Breast Neoplasm Female</condition>
  <arm_group>
    <arm_group_label>NAC not achieving pCR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the study group will accept neo-adjuvant chemotherapy. Among these patients, those who do not achieve pCR after neo-adjuvant chemotherapy will be treated with Capecitabine after surgery. And then they will be followed up for 5 years.
Capecitabine 1000mg/m2 tablets twice a day for 8 cycles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NAC achieving pCR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the study group will accept neo-adjuvant chemotherapy. In these patients, those who reach to pCR after neo-adjuvant chemotherapy will be followed up for 5 years after surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adjuvant Chemotherapy</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients in the control group will accept surgeries and corresponding adjuvant chemotherapy.They will be followed up for 5 years after adjuvant chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Neo-adjuvant Chemotherapy</intervention_name>
    <description>A preoperative chemotherapy based on anthracyclines and taxanes.</description>
    <arm_group_label>NAC not achieving pCR</arm_group_label>
    <arm_group_label>NAC achieving pCR</arm_group_label>
    <other_name>Preoperative Chemotherapy</other_name>
    <other_name>Primary Chemotherapy</other_name>
    <other_name>Induction Chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine 1000mg/m2 tablets twice a day for 8 cycles.</description>
    <arm_group_label>NAC not achieving pCR</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Pathologically confirmed unilateral invasive carcinoma (all pathological types);

          2. No gross or microscopic residual tumor after resection;

          3. Clinical stage Ⅰ-stage Ⅲ A, no absolute surgical contraindications;

          4. Eastern Cooperative Oncology Group(ECOG) score ≤1;

          5. Accepting adjuvant chemotherapy within 15 days after surgery;

          6. No peripheral neuropathy;

          7. Normal bone marrow and organ functions:

               1. Bone marrow function: ANC≥1500/mm3，PLT≥100000/mm3，HGB≥8g/dl

               2. Renal function: serum creatinine≤1.5 times the upper limit of normal(ULN), Liver
                  function: total bilirubin ≤1.5 times the upper limit of normal，AST≤2.5 times the
                  upper limit of normal，alanine aminotransferase(ALT)≤2.5 times the upper limit of
                  normal

               3. Cardiac function:LVEF≥50%

          8. Signed informed consent form.

        Exclusion Criteria:

          1. Patients with the history of oral fluorouracil chemotherapy or Chinese medicine
             treatment;

          2. Patients with organ dysfunction:

               1. Renal function: serum creatinine&gt;1.5 times the upper limit of normal

               2. Liver function: total bilirubin&gt;1.5 times the upper limit of normal，AST&gt;1.5 times
                  the upper limit of normal, alanine aminotransferase(ALT)&gt;1.5 times the upper
                  limit of normal or alkaline phosphatase (ALP) &gt;2.5 times the upper limit of
                  normal

               3. Cardiac function：LVEF&lt;50%;

          3. Human epidermal growth factor receptor-2(HER-2) positive patients who cannot receive
             Herceptin treatment with a left ventricular ejection fraction(LVEF) less than 55%;

          4. Patients allergic to docetaxel, capecitabine, epirubicin and cyclophosphamide;

          5. Patients with severe systemic disease and/or uncontrollable infections;

          6. Patients with previous malignancies, including contralateral breast cancer;

          7. Patients with severe cardiovascular and cerebrovascular disease(i.e. Unstable angina,
             chronic cardiac failure, uncontrollable high blood pressure of &gt;150/90 mmhg,
             myocardial infarction and cerebrovascular accident) history within 6 months before
             randomization;

          8. Pregnant or lactating women.

          9. Patients who have cognitive or psychological impairment as well as cannot understand
             the test program or stand side effects, which will result in a suspension of the trial
             program and follow-up;

         10. Patients without personal freedom or independent civil capacity.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fan Zhimin, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>First Hospital of Jilin University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fan Zhimin, Professor</last_name>
    <phone>+8613756661286</phone>
    <email>fanzhimn@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Han Bing, Professor</last_name>
    <phone>+8613504316519</phone>
    <email>han_bing@jlu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>the First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fan Zhimin, Professor</last_name>
      <phone>+86 13756661286</phone>
      <email>fanzhimn@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Han Bing, Professor</last_name>
      <phone>+86 13504316519</phone>
      <email>han_bing@jlu.edu.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Fisher B, Brown A, Mamounas E, Wieand S, Robidoux A, Margolese RG, Cruz AB Jr, Fisher ER, Wickerham DL, Wolmark N, DeCillis A, Hoehn JL, Lees AW, Dimitrov NV. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997 Jul;15(7):2483-93.</citation>
    <PMID>9215816</PMID>
  </results_reference>
  <results_reference>
    <citation>Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B, Brown AM, Robidoux A, Margolese R, Kahlenberg MS, Paik S, Soran A, Wickerham DL, Wolmark N. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006 May 1;24(13):2019-27. Epub 2006 Apr 10.</citation>
    <PMID>16606972</PMID>
  </results_reference>
  <results_reference>
    <citation>Specht J, Gralow JR. Neoadjuvant chemotherapy for locally advanced breast cancer. Semin Radiat Oncol. 2009 Oct;19(4):222-8. doi: 10.1016/j.semradonc.2009.05.001. Review.</citation>
    <PMID>19732686</PMID>
  </results_reference>
  <results_reference>
    <citation>Mathew J, Asgeirsson KS, Cheung KL, Chan S, Dahda A, Robertson JF. Neoadjuvant chemotherapy for locally advanced breast cancer: a review of the literature and future directions. Eur J Surg Oncol. 2009 Feb;35(2):113-22. doi: 10.1016/j.ejso.2008.03.015. Epub 2008 May 23. Review.</citation>
    <PMID>18502088</PMID>
  </results_reference>
  <results_reference>
    <citation>Mieog JS, van de Velde CJ. Neoadjuvant chemotherapy for early breast cancer. Expert Opin Pharmacother. 2009 Jun;10(9):1423-34. doi: 10.1517/14656560903002105. Review.</citation>
    <PMID>19505212</PMID>
  </results_reference>
  <results_reference>
    <citation>Alliot C. In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer. Ann Oncol. 2005 Sep;16(9):1559-60; author reply 1560-1. Epub 2005 Aug 3.</citation>
    <PMID>16079161</PMID>
  </results_reference>
  <results_reference>
    <citation>Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R, Jukkola-Vuorinen A, Tanner M, Asola R, Kokko R, Ahlgren J, Auvinen P, Hemminki A, Paija O, Helle L, Nuortio L, Villman K, Nilsson G, Lahtela SL, Lehtiö K, Pajunen M, Poikonen P, Nyandoto P, Kataja V, Bono P, Leinonen M, Lindman H; FinXX Study Investigators. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncol. 2009 Dec;10(12):1145-51. doi: 10.1016/S1470-2045(09)70307-9. Epub 2009 Nov 10.</citation>
    <PMID>19906561</PMID>
  </results_reference>
  <results_reference>
    <citation>M Toi, S-J Lee.Abstract S1-07: A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04). American Association for Cancer Research 76(4 Supplement):S1-07,2016</citation>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2017</study_first_submitted>
  <study_first_submitted_qc>January 4, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2017</study_first_posted>
  <last_update_submitted>January 8, 2017</last_update_submitted>
  <last_update_submitted_qc>January 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neo-adjuvant chemotherapy</keyword>
  <keyword>pathological complete response</keyword>
  <keyword>Neoadjuvant Therapy</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>Chemotherapy, Adjuvant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

